About Misols
EN
Imaging beyond pictures
We are redefining the standard of imaging. MISOLS is pioneering the next generation of Multi-Imaging Platforms powered by Photon-counting CT and AI.
Our Philosophy
Understanding the World Through Multi-Layered Data
We do not simplify the world into a single image. Instead, we understand it through multi-dimensional data. While conventional imaging technologies focus on creating the "optimal picture," MISOLS declares that images are not the end result—they are the starting point of data.
We reveal the multi-layered information of how matter responds to energy through multiple spectrums and energy levels. Our approach transforms imaging from visualization into measurement, quantifying the invisible essence that lies beneath the surface.
From Images to Measurements
Image
Visual representation captured by sensors
Data
Digital transformation into quantifiable information
Measurement
Precise quantification of physical properties
Decision
Confident clinical and industrial actions
We are not simply an imaging equipment company. We return images to the realm of measurement, transforming visual data into actionable intelligence. This paradigm shift enables unprecedented precision in diagnosis, quality control, and risk assessment across medical, industrial, and security applications.
The Technical Evolution Chain
1
Detector Physics
Fundamental photon interaction data collection
2
Energy Decomposition
Multi-spectral analysis and separation
3
Quantification
Conversion to precise numerical datasets
4
AI Interpretation
Intelligent pattern recognition and analysis
5
Clinical Decision
Actionable insights for patient care
MISOLS completes a continuous innovation chain from detector physics to clinical decision-making. Each step in this process is optimized to extract maximum value from raw imaging data, ensuring that every photon captured contributes to better outcomes.
Our Vision: Becoming the Global Standard
Imaging beyond pictures
Beyond images to judgment and future. MISOLS aims to become the standard platform company for global medical, security, and industrial imaging.
We integrate detection hardware, processing software, and AI algorithms into a unified ecosystem that transcends traditional modality boundaries. Our platform is designed for scalability and adaptability, ready to meet the evolving needs of diverse industries worldwide.
This vision is grounded in our commitment to field-ready technology—solutions that work flawlessly in real-world clinical and industrial environments, not just in research laboratories.
Our Mission
Integrated Architecture
Seamless hardware-software-AI integration designed from the ground up
Platform Scalability
Modality-independent framework that grows with technology
Field Excellence
Overwhelming technical completeness for real-world deployment
"Connecting multi-imaging technologies to enable more accurate judgment."
Our mission is clear: deliver imaging solutions that enable better decisions. By connecting diverse imaging modalities through a common platform, we eliminate silos and unlock synergies that were previously impossible. This approach accelerates diagnosis, improves quality control, and enhances safety across all applications.
Core Slogan
From Images to Decisions
This is more than a tagline—it's our promise. Every technology we develop, every feature we implement, and every partnership we forge is guided by this principle: transforming visual information into confident, data-driven decisions that improve outcomes and save lives.
The Meaning Behind MISOLS
The MISOLS name represents our commitment to substance over style, science over imagery. Each letter carries meaning that reflects our technical foundation and aspirational goals.
mi
Multi • Micro • Measurement
Representing multiple scales, modalities, and our measurement-first approach
sol
Solution • Spectrum • Solid Physics
Grounded in spectral analysis and solid-state physics principles
s
Systems • Scalability • Science
Systematic, scalable, and scientifically rigorous solutions

MISOLS = A collection of scientific imaging solutions based on multi-physics and multi-spectral foundations
Core Values Driving Innovation
Physics-grounded Innovation
Every breakthrough at MISOLS originates from deep understanding of radiation physics and systems engineering. We don't chase trends—we build on fundamental principles that stand the test of time. Our innovations emerge from rigorous scientific inquiry and are validated through extensive testing before deployment.
Clinical & Field Impact
Technology that exists only in laboratories has limited value. We are committed to creating solutions that perform flawlessly in demanding clinical and industrial environments. Our systems are designed for the realities of 24/7 operation, diverse patient populations, and the complex workflows of modern healthcare and manufacturing facilities.
Open Ecosystem
Growth through collaboration defines our approach. We actively share data, integrate with partner technologies, and contribute to industry standards. Our platform is designed to work seamlessly with existing infrastructure while enabling future innovations. Partner success is MISOLS success.
Compliance by Design
Regulatory compliance and quality assurance are not afterthoughts—they are embedded in every stage of our development process. From initial concept through manufacturing, we design with ISO 13485, IEC 62304, and FDA requirements as integral constraints. This approach ensures global market readiness and builds trust with regulatory bodies worldwide.
Business Overview
Six Core Business Areas
MISOLS operates at the convergence of medical imaging, industrial inspection, and security applications. Our unified platform technology enables expansion into diverse markets while maintaining technical coherence and operational efficiency. Each business area leverages the same core photon-counting and AI capabilities, creating powerful synergies and economies of scale.
This strategic approach allows us to address $50+ billion in combined market opportunities with a single, scalable technology platform. As we grow in one sector, improvements benefit all others—a virtuous cycle of innovation and value creation.
Next-Generation CT Platform
Revolutionary Photon-Counting Technology
Traditional CT scanners integrate photon energy, losing valuable spectral information. Our photon-counting detectors (PCD) capture individual photons and measure their energy levels, unlocking unprecedented diagnostic capabilities.
This fundamental shift in detection physics enables simultaneous multi-energy imaging, material decomposition, and quantitative analysis—all while dramatically reducing radiation dose.
Transformative Benefits
  • 95% radiation dose reduction compared to conventional CT
  • Sub-millimeter spatial resolution for microscopic detail
  • Material-specific quantification for precise tissue characterization
  • Elimination of electronic noise for cleaner images
  • Contrast enhancement without additional injection
Our next-generation CT platform represents the most significant advancement in computed tomography since the invention of spiral scanning. It's not an incremental improvement—it's a complete reimagining of what CT can accomplish.
Medical CT: Precision Personalized Medicine
Material Property Analysis
Our medical CT systems go beyond anatomy to reveal the physical and chemical properties of tissues. This enables early detection of disease based on subtle material changes that precede structural abnormalities.
AI-Enhanced Quantification
Deep learning algorithms trained on massive datasets automatically extract and quantify biomarkers from imaging data, providing objective measurements that reduce inter-observer variability and accelerate diagnosis.
Treatment Optimization
Quantitative imaging enables precise monitoring of treatment response and early detection of complications. Physicians can adjust therapy based on objective data rather than subjective interpretation.
The era of one-size-fits-all medicine is ending. Our ultra-precise imaging enables truly personalized care by revealing the unique characteristics of each patient's disease. This leads to better outcomes, reduced side effects, and lower overall healthcare costs.
Clinical Applications: Transforming Patient Care
Cardiovascular Imaging
Photon-counting CT enables direct quantification of plaque composition, distinguishing calcified, fibrous, and lipid-rich components. This allows precise risk stratification and guides intervention decisions with unprecedented confidence.
Virtual monochromatic imaging eliminates beam-hardening artifacts and reduces metal artifacts from stents, improving diagnostic accuracy in patients with prior interventions.
Oncology
Multi-energy imaging reveals tumor vascularity, perfusion patterns, and metabolic activity without requiring multiple scans or contrast phases. Early changes in these parameters predict treatment response weeks before tumor size changes.
Spectral analysis differentiates tumor from inflammation, reducing false positives and unnecessary biopsies. Material decomposition quantifies iodine uptake as a biomarker for angiogenesis and treatment efficacy.
Industrial CT & Non-Destructive Testing
The same photon-counting technology that revolutionizes medical imaging transforms industrial quality control and materials science. Our industrial CT systems enable non-destructive inspection with micrometer-scale resolution and material-specific contrast.
Battery Technology
Lithium dendrite formation is the primary cause of battery degradation and safety failures. Our systems visualize and quantify dendrite growth in 3D, enabling manufacturers to optimize electrode formulations and predict battery lifespan with unprecedented accuracy. This accelerates development of next-generation high-density batteries for electric vehicles and energy storage.
Semiconductor Inspection
As chip features shrink below 3nm, traditional inspection methods reach their limits. Photon-counting CT reveals subsurface defects, interface delamination, and material inhomogeneities that cause reliability failures. Our systems predict structural degradation mechanisms before devices fail, improving yield and reducing warranty costs.
Additive Manufacturing
3D-printed parts often contain internal porosity and material inconsistencies invisible to surface inspection. Our systems provide complete volumetric analysis, validating part integrity for critical aerospace and medical applications. Material-specific imaging differentiates alloy compositions within multi-material prints.
Security & Safety Scanning
Intelligent Threat Detection
Conventional security scanners rely on density measurements that generate frequent false alarms, requiring manual inspection and slowing throughput. Our atomic number (Z) analysis identifies material composition directly, automatically classifying threats with minimal false positives.
Multi-energy decomposition differentiates explosives, narcotics, and benign organic materials based on their spectral signatures. This enables automated threat classification without opening bags or requiring manual intervention.
01
Rapid Acquisition
High-speed scanning with immediate spectral data collection
02
Material Decomposition
AI-powered atomic number and density analysis
03
Threat Classification
Automatic risk categorization with confidence levels
04
Adaptive Response
Intelligent flagging and automated resolution protocols
Our systems increase security effectiveness while improving passenger experience by reducing wait times and invasive secondary screening. Operators benefit from reduced false alarms and clearer actionable intelligence.
Recycling & Waste Sorting Solutions
Electronic waste contains valuable materials including rare earth elements, precious metals, and hazardous substances requiring careful handling. Manual sorting is inefficient, dangerous, and economically unviable. Our intelligent imaging systems enable automated, high-throughput material recovery.
Nuclear Waste Analysis
Decommissioning nuclear facilities generates complex waste streams requiring precise characterization for safe disposal. Our systems perform non-destructive assay of radioactive materials, identifying isotopes and quantifying concentrations without exposing workers to hazards.
Multi-energy imaging discriminates between low-level, intermediate-level, and high-level waste, optimizing disposal costs and ensuring regulatory compliance. Real-time analysis accelerates decommissioning projects and reduces overall costs.
Resource Recovery
Electronic devices contain gold, silver, palladium, and rare earth elements worth billions annually. Our systems identify and sort components by material composition at high speed, enabling profitable recovery of valuable materials.
Spectral analysis distinguishes similar-appearing plastics for recycling, increasing purity and value of recycled material streams. This transforms waste from a disposal problem into a valuable resource.
Data Platform Ecosystem
Our intelligent platform transforms the challenges of vast imaging data into opportunities for breakthrough discoveries.
Data Volume & Richness
Imaging generates enormous data volumes, yet most raw detector data, rich in spectral characteristics and subtle material differences, is discarded after diagnosis.
Platform Capabilities
Our platform captures, standardizes, and connects raw imaging data from diverse sources, creating a unified resource for AI development.
AI Training & Analysis
Enables large-scale model development on diverse datasets, transforming raw data into actionable insights and supporting clinical research.
Value Creation & Insights
Accelerates drug discovery and provides improved algorithms, creating a continuous loop of innovation and benefiting the entire ecosystem.
Accelerating Drug Development
Clinical trials are the most expensive and time-consuming phase of drug development, often requiring years and hundreds of millions of dollars. Imaging biomarkers can dramatically accelerate this process by providing early, objective measures of drug efficacy.
Our data platform connects imaging data with clinical outcomes across thousands of patients, enabling identification of predictive biomarkers. Pharmaceutical companies can use these biomarkers to:
Reduce clinical trial size and duration
Identify responsive patient subpopulations
Detect efficacy signals earlier in development
Optimize dosing regimens
Monitor treatment response in real-time
This transforms imaging from a diagnostic tool into an integral component of precision medicine development, reducing the time and cost to bring life-saving therapies to patients.
Leadership
Dr. Minkook Cho, CEO & Founder
Visionary Leadership
Dr. Cho has over two decades of experience in medical device development, systems engineering, and commercialization. He designed complete medical CT systems, showcasing rare end-to-end expertise.
2008-2009
Researcher, National Cancer Center: Developed the world's first proton CT imaging system and CT-based patient positioning for radiation therapy.
2010-2021
Leadership roles at Samsung Electronics.
2021-2025
Research Director, Osstem Implant.
2022-2025
Osstem Global CTO: Built R&D organizations, established international operations, and navigated regulatory environments.
2024-2025
Osstem Global CEO.
2026
Founded MISOLS.
Academic Contributions
Academic Appointments
Adjunct Professor at Pusan National and Yonsei Universities. Facilitates technology transfer and keeps MISOLS at the forefront of academic research.
Extensive Publications
Published extensively on CT imaging physics, detector technology, and image reconstruction. Bridges fundamental physics with clinical applications.
Track Record of Innovation
1
National Cancer Center (2008-2009)
Spearheaded the development of the world's first proton CT imaging system and a CT-based patient positioning system for radiation therapy.
2
Samsung Electronics (2010-2021)
Led development teams for advanced imaging systems and medical device platforms.
3
Osstem Implant Research Director (2021-2025)
Pioneered digital dentistry and 3D imaging as Director of Research Institute.
4
Osstem Global CTO (2022-2025)
Built high-performing R&D organizations and established international operations.
5
Osstem Global CEO (2024-2025)
Navigated complex regulatory environments and achieved global regulatory approvals.
6
MISOLS Founded (2026)
Established company to commercialize next-generation multi-imaging platform.
Dr. Cho's achievement in obtaining FDA clearance for the world's first mobile photon-counting CT system demonstrates his ability to navigate complex technical and regulatory challenges. This milestone validates both the technology and the regulatory strategy that will enable rapid market entry for MISOLS products.

Patent Portfolio: Dr. Cho holds dozens of global patents covering photon-counting detector design, image reconstruction algorithms, spectral processing, and system integration. This intellectual property creates substantial barriers to entry and provides long-term competitive advantage.
World-Class Engineering Expertise
Detector Physics
Deep understanding of photon interaction mechanisms, semiconductor detector response, and pulse processing electronics. This knowledge enables optimization of detector materials, geometries, and readout architectures for maximum performance.
System Integration
Expertise in gantry design, thermal management, power distribution, and electromagnetic compatibility. These system-level considerations are critical for reliable operation in demanding clinical environments.
Image Reconstruction
Advanced knowledge of iterative reconstruction, model-based algorithms, and spectral decomposition techniques. Our proprietary algorithms extract maximum information from raw detector data while minimizing computational requirements.
Clinical Translation
Understanding of clinical workflows, diagnostic requirements, and user needs ensures that technical capabilities translate into practical clinical value. Technology must serve clinicians, not complicate their work.
Quality & Compliance
Compliance Is Not Optional—It Is Default
"Compliance is not an option. It is the default."
Medical device development requires rigorous adherence to quality management standards and regulatory requirements. Many companies treat compliance as a burden to be minimized. At MISOLS, we embrace regulatory requirements as quality drivers that ultimately benefit our customers.
Our design control process incorporates ISO 13485, IEC 62304, and FDA 21 CFR Part 820 requirements from project inception. This "compliance by design" approach ensures that quality and safety are built into products rather than inspected in after development.
Global Regulatory Strategy
FDA (United States)
510(k) and De Novo pathways for novel technologies
Design control and risk management documentation
Clinical evaluation and performance testing
Post-market surveillance and complaint handling
CE Mark (Europe)
MDR compliance for medical device regulation
Technical documentation and clinical evaluation
Notified body assessment and certification
Post-market clinical follow-up
NMPA (China)
Class III medical device registration
Clinical trial requirements and data
Manufacturing quality system audit
Local representative and service network
PMDA (Japan)
Shonin approval for novel medical devices
Japanese language documentation
Local clinical data requirements
Kaizen quality improvement processes
Our regulatory strategy prioritizes major markets while maintaining flexibility for emerging opportunities. Parallel development tracks enable simultaneous submissions to multiple agencies, accelerating global commercialization.
Quality Management System
ISO 13485 Certification
Our quality management system meets international standards for medical device manufacturers. This certification demonstrates our commitment to consistent product quality, regulatory compliance, and continuous improvement.
Regular internal and external audits verify system effectiveness and identify opportunities for enhancement. Management review ensures that quality objectives align with business strategy.
Risk Management
ISO 14971 risk management processes are integrated throughout the product lifecycle. We systematically identify hazards, estimate risks, implement controls, and verify effectiveness.
Risk-benefit analysis informs design decisions and regulatory submissions. Residual risks are clearly communicated to users through labeling and training materials.
Manufacturing Excellence
Quality begins with robust manufacturing processes. Our production facilities are designed for cleanroom assembly of sensitive detector components, precision mechanical fabrication, and comprehensive testing of complete systems.
Component Qualification
Rigorous supplier selection and incoming inspection ensure that only materials meeting specifications enter production. Statistical process control monitors key parameters.
Assembly Validation
Work instructions and visual aids guide assembly operations. Built-in quality checks at each step prevent defects from propagating. First article inspection validates new processes.
System Testing
Every unit undergoes comprehensive performance testing including image quality assessment, radiation safety verification, and electrical safety validation. Test data is retained for traceability.
Final Inspection
Independent quality assurance review confirms that all requirements are met before release. Calibration certificates and test reports accompany each shipment.
Partnerships
Building Standards Together
MISOLS does not operate in isolation. We actively seek partnerships with hospitals, research institutions, industrial customers, and investors who share our vision of transforming imaging into a quantitative science.
Our open platform approach enables integration with complementary technologies and facilitates data sharing for collective benefit. Partner success is MISOLS success—we grow together by creating value for the entire ecosystem.
"The possibilities of imaging become 'standards' when we create them together. Your success is our platform's success."
Clinical Partnerships
Academic Medical Centers
Leading research hospitals provide access to diverse patient populations, clinical expertise, and rigorous evaluation of new technologies. These partnerships generate clinical evidence supporting regulatory submissions and publications in peer-reviewed journals. Early adopter sites become reference centers that influence broader adoption.
Radiology Groups
Private practice radiologists offer pragmatic feedback on workflow integration, productivity impact, and economic value. Their insights ensure that our systems meet the realities of high-volume clinical practice. These partnerships often evolve into commercial relationships as technologies prove their value.
Clinical Trials
Pharmaceutical and biotech companies seek validated imaging biomarkers for drug development. Our data platform and quantitative imaging capabilities accelerate their research while generating revenue and expanding our clinical evidence base. These collaborations often lead to long-term service agreements.
Industrial Partnerships
Manufacturing Integration
Industrial customers require seamless integration with existing production lines, automated data transfer to quality management systems, and minimal operator intervention. We work closely with manufacturing engineers to customize solutions for specific applications.
These partnerships often reveal new use cases and drive product enhancements benefiting all customers. Industrial feedback accelerates our development roadmap and ensures market relevance.
Technology Alliances
No single company can provide complete solutions for complex imaging challenges. We partner with leaders in robotics, automation, artificial intelligence, and data analytics to deliver integrated systems greater than the sum of their parts.
These alliances expand our addressable market, accelerate product development, and strengthen competitive position through complementary capabilities.
Investment Partnership Opportunities
MISOLS represents a compelling investment opportunity at the intersection of multiple high-growth markets. Our technology platform addresses needs in medical imaging ($40B+ market), industrial inspection ($15B+ market), and security screening ($10B+ market). A single R&D investment creates products for all three sectors.
$65B+
Total Addressable Market
Combined opportunity across medical, industrial, and security applications
18%
Annual Market Growth
CAGR driven by aging populations, quality demands, and security concerns
95%
Dose Reduction
Transformative clinical benefit enabling new applications
4-6x
Performance Advantage
Resolution, contrast, and quantification vs. conventional systems
Competitive Advantages
Proprietary Technology
Decades of development in photon-counting CT crystallized into a comprehensive patent portfolio. Our detector designs, reconstruction algorithms, and system architectures are protected by IP that cannot be easily replicated. This creates multi-year competitive lead time.
Platform Leverage
Unlike competitors focused on single modalities or markets, our unified platform enables rapid product derivatives. Engineering investment in core technologies benefits multiple product lines, improving R&D efficiency and accelerating time-to-market for new applications.
Regulatory Expertise
Proven ability to navigate FDA, CE Mark, and other regulatory processes. Our FDA breakthrough device designation and clearance of the world's first mobile PCD-CT demonstrates regulatory strategy effectiveness. This expertise accelerates product launches and reduces compliance risk.
Market Timing
Healthcare systems worldwide face pressure to improve outcomes while controlling costs. Our technology directly addresses these needs through better diagnosis with lower dose and automated quantitative analysis. Industrial and security markets similarly demand higher performance with lower operating costs.
Go-to-Market Strategy
Our commercialization strategy balances rapid market entry with sustainable growth. We focus initial efforts on markets with highest unmet needs, favorable reimbursement, and shorter regulatory pathways. Success in these beachhead markets provides references and cash flow supporting broader expansion.
1
Phase 1: Clinical Validation
Partner with leading academic medical centers for clinical studies and publications. Build evidence base supporting regulatory submissions and reimbursement applications.
2
Phase 2: Limited Launch
Initial commercial sales to early adopter hospitals and research institutions. Focus on high-value applications with clear ROI. Establish service and support infrastructure.
3
Phase 3: Market Expansion
Broaden product portfolio and target markets. Increase production capacity and geographic coverage. Develop strategic partnerships for distribution and service.
4
Phase 4: Platform Dominance
Establish MISOLS as the standard platform for quantitative imaging. Expand data ecosystem and AI capabilities. Leverage network effects to maintain leadership position.
Financial Projections
Revenue Growth
We project achieving profitability within 4-5 years as product portfolio expands and manufacturing scales. Initial revenues from high-margin research systems and industrial applications provide cash flow supporting medical product development.
Medical CT systems represent largest long-term opportunity with unit sales potential exceeding 1,000 systems annually at maturity. Industrial and security products provide diversification and stability.
These projections assume successful regulatory approvals, manufacturing scale-up, and market acceptance consistent with our clinical evidence and competitive advantages. Conservative assumptions provide confidence in achievability while significant upside exists if market adoption accelerates.
Use of Investment Proceeds
40%
Product Development
R&D for next-generation detectors, AI algorithms, and new applications. Clinical studies and regulatory submissions.
25%
Manufacturing
Production equipment, facilities expansion, quality systems, and supply chain development for commercial-scale manufacturing.
20%
Sales & Marketing
Building commercial organization, marketing programs, trade show presence, and KOL engagement to drive adoption.
15%
Operations
Infrastructure, IT systems, quality/regulatory staff, and working capital to support rapid growth and global operations.
This allocation balances near-term product development with building the commercial and operational infrastructure required for long-term success. All investments are designed to create scalable capabilities that support multiple product lines and markets.
Investment Highlights
Massive Market Opportunity
$65B+ addressable market across medical, industrial, and security sectors with strong growth drivers and limited competition for our unique capabilities.
Defensible Technology
Extensive patent portfolio and regulatory approvals create substantial barriers to entry. Years of development cannot be quickly replicated.
Proven Leadership
World-class technical team with track record of successful product development and commercialization. FDA clearance validates approach.
Global Scalability
Platform architecture enables rapid geographic and application expansion. Single R&D investment creates products for multiple high-value markets.
MISOLS represents a rare opportunity to invest in transformative technology at an inflection point. The convergence of technical maturity, market readiness, and experienced leadership positions the company for exceptional growth.
Innovation Vision
Beyond Imaging: The Future We're Building
The transformation from images to measurements is just the beginning. As photon-counting technology matures and AI capabilities advance, imaging will become an integral component of precision medicine, smart manufacturing, and intelligent infrastructure.
We envision a future where quantitative imaging is as routine as laboratory testing, where treatment decisions are guided by objective biomarkers rather than subjective interpretation, and where quality control is automated through real-time material characterization.
"We are building the measurement infrastructure for a data-driven future."
AI-Powered Diagnostic Ecosystem
Automated Analysis
Deep learning models trained on millions of images will automate routine image interpretation, freeing radiologists to focus on complex cases and patient interaction. AI will detect subtle findings humans might miss while reducing inter-observer variability.
These algorithms will continuously improve as they process more data, creating a virtuous cycle of increasing accuracy and expanded capabilities. Federated learning enables model training across institutions while preserving patient privacy.
Predictive Analytics
Quantitative imaging biomarkers combined with clinical data and genomics will enable prediction of disease progression and treatment response. This shifts medicine from reactive to proactive, intervening before symptoms develop.
Risk stratification models will identify patients who benefit most from intensive monitoring or preventive interventions, optimizing resource allocation and improving outcomes while controlling costs.
Personalized Treatment Planning
Disease Characterization
Quantitative imaging reveals unique characteristics of each patient's disease including tumor biology, cardiovascular risk factors, or tissue composition
Multi-Modal Integration
Imaging data combines with genomics, proteomics, and clinical history to create comprehensive patient model
Therapy Selection
AI algorithms predict response to different treatment options, guiding selection of optimal therapy for individual patient
Response Monitoring
Quantitative tracking of treatment effects enables early detection of non-responders and rapid adjustment of therapy
Smart Manufacturing Revolution
Integration of quantitative imaging into production lines will enable real-time quality control at manufacturing speeds. Every product will be inspected with x-ray vision, detecting defects invisible to human inspectors or surface-scanning technologies.
Machine learning algorithms will identify subtle patterns predicting failure modes, enabling predictive maintenance and process optimization. This reduces waste, improves yield, and accelerates time-to-market for new products.
01
Inline Inspection
Real-time imaging of products during manufacturing
02
Automated Analysis
AI classifies defects and predicts failure risk
03
Process Adjustment
Feedback controls manufacturing parameters
04
Continuous Improvement
Data accumulation drives process optimization
Digital Twin Integration
Quantitative imaging enables creation of high-fidelity digital twins—virtual replicas of physical objects updated in real-time with sensor data. For manufactured products, digital twins predict remaining useful life and optimize maintenance schedules.
In healthcare, patient-specific digital twins will enable virtual testing of treatment options before implementation. Surgeons will rehearse complex procedures on accurate 3D models. Drug developers will predict individual patient response before enrollment in clinical trials.
These digital twins require accurate geometric and material property information that only quantitative imaging can provide. MISOLS technology is the foundation enabling this digital transformation across industries.
Global Health Impact
Accessible Imaging
Reduced size, power consumption, and cost of photon-counting systems enable deployment in underserved areas. Mobile and point-of-care imaging brings advanced diagnostics to remote locations lacking traditional radiology infrastructure.
Telemedicine Integration
High-quality quantitative data enables remote interpretation by specialists anywhere in the world. AI-assisted analysis provides preliminary results immediately while expert review proceeds asynchronously, improving access to specialized care.
Education & Training
Comprehensive imaging databases with quantitative annotations accelerate training of radiologists and technologists. AI tutoring systems provide immediate feedback on interpretation accuracy. Virtual reality integration creates immersive educational experiences.
Environmental Sustainability
Reduced Radiation Exposure
Photon-counting CT's 95% dose reduction eliminates a major barrier to screening programs and longitudinal monitoring studies. Lower radiation exposure enables safe imaging of pediatric patients and pregnant women when medically necessary.
Cumulative radiation dose reduction across millions of patients represents a significant public health benefit, reducing cancer risk while enabling better medical care.
Resource Efficiency
Improved recycling through material-specific sorting reduces mining of virgin materials and energy consumption in manufacturing. Recovery of valuable materials from electronic waste provides economic incentive for proper disposal rather than landfilling or incineration.
Energy-efficient detector and reconstruction algorithms reduce power consumption of imaging systems, lowering operating costs and environmental impact. Cloud-based processing enables efficient utilization of computing resources through load balancing and optimization.
Ethical Considerations & Data Privacy
The power of quantitative imaging and AI raises important ethical questions about data ownership, algorithmic bias, and appropriate use of predictive information. MISOLS is committed to addressing these challenges proactively through transparent policies and technological safeguards.
Data Protection
All patient data is encrypted in transit and at rest using industry-standard protocols. Access controls ensure that only authorized personnel can view sensitive information. De-identification protects privacy while enabling research.
Algorithmic Fairness
AI models are trained on diverse datasets representing different populations, reducing bias in predictions. Regular audits assess performance across demographic groups. Transparency reports document model development and validation.
Informed Consent
Patients understand how their imaging data will be used, who has access, and what benefits and risks are involved. Easy-to-understand consent forms empower individuals to make informed decisions about participation in research.
Governance Framework
Ethics review boards evaluate new applications before deployment. Data use agreements specify permitted uses and prohibit discriminatory practices. Regular compliance audits ensure adherence to policies.
Technology Roadmap
2024-2025
Product Launch: First commercial medical CT systems
Regulatory: Additional FDA clearances and CE marks
Partnerships: Clinical and industrial collaborations
2025-2026
Portfolio Expansion: Industrial CT and security products
AI Development: Deep learning algorithms for automated analysis
Data Platform: Launch multi-site data ecosystem
2026-2027
Global Expansion: Enter Asian and European markets
Next Generation: Advanced detector materials and architectures
Integration: Partnerships with EMR and PACS vendors
2027-2028
Platform Maturity: Comprehensive product portfolio
Market Leadership: Established as standard platform
Ecosystem: Thriving partner and developer community
This roadmap balances aggressive innovation with realistic development timelines. Each milestone builds on previous achievements, reducing risk while maintaining momentum. Flexibility allows adaptation to market feedback and emerging opportunities.
Risk Factors & Mitigation
Like all technology ventures, MISOLS faces risks that could impact business success. We have identified key risks and developed mitigation strategies to minimize their probability and impact.
Regulatory Risk
Challenge: Delays or denials in regulatory approvals could postpone product launches and revenue generation.
Mitigation: Experienced regulatory team with proven track record. Early engagement with agencies. Conservative timelines and contingency plans. Pre-submission meetings to align expectations.
Technology Risk
Challenge: Technical challenges in scaling from prototype to production could increase costs or delay timelines.
Mitigation: Proven technology demonstrated in FDA-cleared system. Conservative design margins. Phased development approach with frequent testing. Experienced engineering team.
Market Adoption Risk
Challenge: Slower than anticipated customer adoption could reduce revenue growth and delay profitability.
Mitigation: Strong clinical evidence of value. Key opinion leader endorsements. Multiple market segments provide diversification. Flexible pricing models address different customer needs.
Competition Risk
Challenge: Large competitors could develop competing products or acquire smaller companies with similar technology.
Mitigation: Patent portfolio creates barriers to entry. First-mover advantage in emerging applications. Platform approach spans multiple markets. Partnership strategy provides distribution and credibility.
Exit Opportunities
MISOLS' technology and market position make it an attractive acquisition target for established medical device companies, industrial inspection firms, or technology conglomerates seeking to enter the imaging market. Multiple exit scenarios provide liquidity opportunities for investors.
Strategic Acquisition
Large medical device companies including GE HealthCare, Siemens Healthineers, Philips, and Canon Medical actively pursue innovative imaging technologies through acquisitions. Our photon-counting platform and IP portfolio would provide significant strategic value to these acquirers.
Industrial inspection companies like Zeiss, Nikon, and Bruker seek advanced CT capabilities for materials characterization and quality control applications. Our technology addresses their needs across automotive, aerospace, and electronics sectors.
IPO Potential
If the company achieves strong revenue growth and profitability, an initial public offering becomes viable. Recent medical device IPOs have achieved attractive valuations, particularly for companies with differentiated technology and clear competitive advantages.
Public markets increasingly value technology-enabled healthcare companies combining hardware, software, and data assets. MISOLS' platform approach and multiple revenue streams fit this profile.
Comparable Transactions
Recent acquisitions in the imaging and medical device sectors demonstrate strong investor interest and attractive valuation multiples. These transactions provide benchmarks for potential exit values.
Prismatic Sensors (2021)
Acquired by Mars Petcare for $150M. Developed photon-counting CT for veterinary applications. Transaction valued company at 8x revenue, demonstrating premium for photon-counting technology.
Varian Medical Systems (2020)
Acquired by Siemens Healthineers for $16.4B. Leading radiation oncology company with complementary imaging business. Transaction at 5x revenue highlighted value of integrated therapy and imaging platforms.
Hyperfine (2021)
SPAC merger valued at $580M. Portable MRI company with AI analysis capabilities. Demonstrated investor appetite for innovative imaging modalities with AI integration.
Butterfly Network (2021)
SPAC merger valued at $1.5B pre-money. Handheld ultrasound with AI interpretation. Premium valuation for portable imaging with software platform approach similar to MISOLS strategy.
These transactions suggest valuation multiples of 5-8x revenue for mature companies and higher multiples for high-growth, technology-differentiated businesses. MISOLS' platform approach spanning multiple markets could command premium valuation.
Contact Us
Partner With MISOLS
We welcome inquiries from investors, clinical partners, industrial customers, and technology collaborators who share our vision of transforming imaging into quantitative measurement. Together, we can establish new standards and create value for all stakeholders.
Investment Inquiries
Institutional investors and strategic partners interested in participating in our growth story
Contact: investors@misols.com
Clinical Partnerships
Hospitals and research institutions interested in clinical studies and early adoption programs
Contact: clinical@misols.com
Industrial Collaboration
Manufacturing companies seeking advanced inspection capabilities and quality control solutions
Contact: industrial@misols.com
Technology Licensing
Companies interested in licensing our technology or exploring strategic technology partnerships
Contact: licensing@misols.com
Building the Future Together
Join Our Journey
MISOLS is more than a technology company—we are a community of scientists, engineers, clinicians, and business leaders united by a common vision of transforming imaging from art to science.
We seek partners who bring complementary expertise, share our commitment to excellence, and are excited about creating something unprecedented. Whether you are an investor providing capital, a clinician contributing expertise, or a technology partner enabling integration, your success is our success.
The transformation from images to decisions requires collaboration across disciplines and industries. No single company can achieve this vision alone. Together, we can establish new standards that benefit patients, improve manufacturing quality, and enhance security worldwide.
MISOLS: Redefining Imaging Standards
From our foundational philosophy of understanding the world through multi-layered data to our comprehensive business strategy spanning medical, industrial, and security applications, MISOLS represents a paradigm shift in imaging technology.
Our photon-counting CT platform, AI-powered analytics, and commitment to regulatory excellence position us to become the global standard for quantitative imaging. With proven leadership, defensible intellectual property, and massive market opportunities, we offer investors exceptional growth potential.
"We are not just creating better images. We are building the measurement infrastructure for precision medicine, smart manufacturing, and intelligent security. We are transforming uncertainty into confidence, images into decisions, and vision into reality."
The future of imaging is quantitative, multi-modal, and AI-enabled. The future of imaging is MISOLS.
Imaging beyond pictures
Thank you for your interest in MISOLS. We look forward to partnering with you to transform the standard of imaging worldwide.
MISOLS Inc. | Imaging beyond pictures | From Images to Decisions